Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
RESEARCH TRIANGLE PARK, N.C., April 24, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2017 financial results will be reported on Thursday, May 4th, 2017.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company’s clinical development programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and is currently marketed in the U.S., Japan, Taiwan and Korea. Post-marketing commitment development activities are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
